RxDoctor Payments Data

Beverly Jordan, MD

Family Medicine · Enterprise, ALNPI 1205891702

Payments from drug & device makers

$12,272in general payments, 2019–2025

Across 955 payments — averaging $12.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • Novo Nordisk$966
  • Lilly USA, LLC$956
  • Amgen$915
  • Pfizer$907
  • plus $6K from 42 others

What the payments were for

  • Food & beverage$12,250100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,272 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$335,041
Medicare patients
338
Services billed
16,544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$70,833
JardianceEmpagliflozin42$54,078
JanuviaSitagliptin Phosphate42$50,202
MounjaroTirzepatide32$44,902
EliquisApixaban45$43,743
OzempicSemaglutide44$42,112
MyrbetriqMirabegron46$30,386
NuedextaDextromethorphan Hbr/Quinidine14$22,440
Repatha SureclickEvolocumab29$16,124
TrulicityDulaglutide16$15,396
ShingrixVaricella-Zoster Ge/As01b/Pf69$15,276
Breo ElliptaFluticasone/Vilanterol11$10,905
XareltoRivaroxaban17$10,570
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$10,352
ArexvyRsvpref3 Antigen/As01e/Pf21$6,415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta, Arexvy$1,327$113,782203 claims
Lilly USA, LLCMounjaro, Trulicity$956$60,29848 claims
Boehringer IngelheimJardiance$472$54,07842 claims
MerckJanuvia$189$50,20242 claims
PfizerEliquis$907$43,74345 claims
Novo NordiskOzempic, Novolog$966$43,45861 claims
Johnson & JohnsonXarelto$685$10,57017 claims
AstraZenecaSymbicort$901$3,01714 claims
Sanofi-aventis U.S. LLCLantus$127$1,94619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Enterprise

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →